Medpace Inc. (MEDP)
Medpace Inc. (MEDP) Stock Price, Analysis & Data
| Bid | 604.56 |
| Market Cap | 16.67B |
| Revenue (ttm) | 2.78B |
| Net Income (ttm) | 491.5M |
| Beta | 1.15 |
| EPS (ttm) | 17.56 |
| PE Ratio (ttm) | 34 |
| Forward PE | 30.92 |
| P/B (ttm) | 38.41 |
| P/S (ttm) | 5.99 |
| Earnings Date | Oct 19, 2026 |
| Ask | 595.52 |
| Volume | 162,612 |
| Avg. Volume (20D) | 321,519 |
| Open | 578.29 |
| Previous Close | 578.50 |
| Day's Range | 571.01 - 597.47 |
| 52-Week Range | 373.00 - 677.90 |
| Analyst | n/a |
| Price Target | 604.5 (1.24%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, c...
Financial Performance
In 2025, Medpace's revenue was 2.53B, an increase of 19.97% compared to the previous year's 2.11B. Earnings were 451.12M, an increase of 11.56%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for MEDP stock is "null". The 12-month stock price forecast is 604.5, which is upside of 1.24% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
